A Study to Assess the Effects of Bempedoic Acid in Patients with or at high risk for Cardiovascular Disease
Status: open17-108 - A Randomized, Double-Blind, Placebo-Controlled study to Assess the Effects of Bempedoic Acid (ETC-1002) on the occurrence of Major Cardiovascular Events in Patients with, or at High Risk for Cardiovascular Disease who are Statin-Intolerant
Treatment for Cardiovascular Disease
Description
The primary objective is to evaluate whether administration of bempedoic acid 180 mg/day versus placebo reduces the risk of MACE in patients with, or at high risk for, CVD who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization. IRB Number 17-108
Sponsors
This trial is sponsored by Esperion Therapeutics, Inc..Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at 251-471-7027 or by email at crevere@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Bassam Omar]()
View ProfileBassam A. Omar, M.D., Ph.D., F.A.C.C.CardiologistFellowship Director of Cardiovascular Diseases; Professor of Internal Medicine
Sub Investigators
![Ghulam Mustafa Awan]()
View ProfileGhulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine
